Actively Recruiting
Evaluating Safety and Effectiveness of Mosaic Injectable Dermal Implant for Midface Volume Deficit in Adults
Led by Helios Aesthetics Inc. · Updated on 2026-08-24
50
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of the Mosaic Injectable Dermal Implant for treating age-related midface volume loss in adults aged 22 years and older. This study aims to track any medical issues participants may experience over 12 months after treatment and measure how much the implant improves midface volume six months after injection. Participants will receive up to 12 mL of the Mosaic Injectable Dermal Implant, divided into two injections spaced one month apart, with a maximum of 6 mL per session. If needed, a touch-up injection may be given one month after the initial treatment. The implant is delivered via injections to the midface to restore volume. During the study, participants will visit the clinic after each injection and at 3, 6, and 12 months post-treatment for facial photos to document volume changes. They will also keep a diary for 30 days after each injection to record any symptoms possibly related to the treatment. Researchers will monitor adverse events and evaluate the implants effectiveness using standardized volume scoring at set intervals throughout the year-long study.
CONDITIONS
Brief Title
Safety and Effectiveness of Mosaic for the Treatment of Midface Volume Deficit
Research Team
C
Chief Operations Officer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here